Net Cash Provided by (Used in) Financing Activities of VACCINEX, INC. from 31 Dec 2017 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
VACCINEX, INC. annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2017 to 31 Dec 2024.
  • VACCINEX, INC. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2024 was $6,069,000, a 200% increase year-over-year.
  • VACCINEX, INC. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $15,780,000, a 4.9% decline from 2023.
  • VACCINEX, INC. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $16,590,000, a 2.3% decline from 2022.
  • VACCINEX, INC. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $16,975,000, a 27% decline from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

VACCINEX, INC. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $15,780,000 -$810,000 -4.9% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025 2024 FY
2023 $16,590,000 -$385,000 -2.3% 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025 2024 FY
2022 $16,975,000 -$6,348,000 -27% 01 Jan 2022 31 Dec 2022 10-K/A 25 Apr 2024 2023 FY
2021 $23,323,000 -$13,434,000 -37% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2020 $36,757,000 +$22,957,000 +166% 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
2019 $13,800,000 -$27,155,000 -66% 01 Jan 2019 31 Dec 2019 10-K 31 Mar 2021 2020 FY
2018 $40,955,000 +$16,981,000 +71% 01 Jan 2018 31 Dec 2018 10-K 09 Mar 2020 2019 FY
2017 $23,974,000 01 Jan 2017 31 Dec 2017 10-K 13 Mar 2019 2018 FY

VACCINEX, INC. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $6,069,000 +$4,048,000 +200% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q1 2023 $2,021,000 -$11,189,000 -85% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q1 2022 $13,210,000 -$12,697,000 -49% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q1 2021 $25,907,000 +$18,428,000 +246% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q1 2020 $7,479,000 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1
Q1 2018 $3,956,000 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.